Inhalation Sciences Sweden AB releases Year-end Report January 1 - 31 December 2021 Inhalation Sciences AB announces that its Year-end Report 1 January - 31 December 2021 is. | February 28, 2022
In a renewed partnership Karolinska Institutet in Stockholm will help validate ISAB s new XposeALI® MP tool, including using it to test a Mars dust surrogate for the European Space Agency. | October 12, 2021
April 20, 2021)
Inhalation Sciences (ISAB) has signed an agreement with prestigious lead generation company Cience and with Coelus Bio, a boutique CRO consulting firm specialized in inhalation drug development, to generate new leads and sales in the US. It is part of the marketing activities aimed at growing ISAB s sales and presence in the US, a strategic goal for 2021, and becoming a clear market leader in its niche.
With strengthened sales in 2020 ISAB identified expanding its marketing and sales activities as a vital strategy for 2021, aiming to expand sales in the US . In
December 2020 the company announced a new partnership with global branding agency Up, in early 2021 ISAB has rolled out new messaging and branding actions in targeted trade channels, and it will soon be strengthening its digital presence with the launch of a new website.
We re Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability
By
December 29, 2020 Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability suggests a business is sustainable. That said, the current statutory profit is not always a good guide to a company s underlying profitability. In this article, we ll look at how useful this year s statutory profit is, when analysing
Inhalation Sciences Sweden (NGM:ISAB). It s good to see that over the last twelve months Inhalation Sciences Sweden made a profit of kr11.7m on revenue of kr12.1m. The chart below shows that revenue has improved over the last three years, and, even better, the company has moved from unprofitable to profitable.